RxDoctor Payments Data

Harvey Hashimoto, MD

Family Medicine · Lodi, CANPI 1578506952

Payments from drug & device makers

$17,834in general payments, 2019–2025

Across 572 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$7K
  • Mimedx Group, Inc.$3K
  • Smith+Nephew$2K
  • AstraZeneca$633
  • Lilly USA, LLC$629
  • Novo Nordisk$607
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$2,48614%
  • Food & beverage$15,34286%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,834 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$151,864
Medicare patients
239
Services billed
5,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$49,886
XareltoRivaroxaban21$33,284
OxycontinOxycodone Hcl13$32,651
RybelsusSemaglutide24$29,332
LinzessLinaclotide16$17,468
EliquisApixaban17$14,870
TrulicityDulaglutide12$14,228
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen249$8,784
Breo ElliptaFluticasone/Vilanterol11$5,821
Fentanyl30$3,289
Morphine Sulfate ErMorphine Sulfate37$2,082
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen78$1,693
Albuterol Sulfate HfaAlbuterol Sulfate45$1,528
Linezolid22$1,183
Oxycodone Hcl24$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$169$49,88638 claims
Johnson & JohnsonXarelto$483$33,28421 claims
Novo NordiskRybelsus$607$29,33224 claims
AbbVieLinzess$577$17,46816 claims
PfizerEliquis$41$14,87017 claims
Lilly USA, LLCTrulicity$629$14,22812 claims
GSKBreo Ellipta$113$5,82111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →